The cell and gene therapy (C&GT) environment is changing, with an increasing focus toward larger indications with relatively lower unmet needs alongside the potential for increased competition with multiple C&GTs launching in the same indication. In this white paper by Precision’s Richard Macaulay, we explore how payers will respond to a changing C&GT landscape and how innovative reimbursement strategies for these therapies might evolve.

Read now!